


REMARKS

Applicants have amended the claims to recite more clearly and distinctly that which applicants consider their invention. Specifically, the claims are amended to conform to U.S. practice. All amendments are supported by the specification as originally filed. Entry of the claim amendments and early favorable consideration of the claims are earnestly solicited.

If there are any questions regarding this amendment or the application in general, a telephone call to the undersigned would be appreciated since this should expedite the prosecution of the application for all concerned.

If necessary to effect a timely response, this paper should be considered as a petition for an Extension of Time sufficient to effect a timely response, and please charge any deficiency in fees or credit any overpayments to Deposit Account No. 05-1323 (Docket #1736/49753).

Respectfully submitted,




J. D. Evans
Registration No. 26,269
Kening Li, Ph.D.
Registration No. 44,872

CROWELL & MORING, LLP
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JDE:KL:tlm
(CAM #: 37116.005)

VERSION WITH MARKINGS TO SHOW CHANGES MADE

1. (Amended) An hydrophobic GRF analog of formula A:



wherein [5]

the GRF peptide is a peptide of formula B;

A1-A2-Asp-Ala-Ile-Phe-Thr-A8-Ser-Tyr-Arg-Lys-A13-

Leu-A15-Gln-Leu-A-18-Ala-Arg-Lys-Leu-Leu-A24-A25-

Ile-A27-A28-Arg-A30-R₀ (B)

A1 is Tyr or His;

A2 is Val or Ala;

A8 is Asn or Ser;

A13 is Val or Ile;

A15 is Ala or Gly;

A18 is Ser or Tyr;

A24 is Gln or His;

A25 is Asp or Glu;

A27 is Met, Ile or Nle;

A28 is Ser or Asn;

A30 is a bond or any amino acid sequence of 1 [up] to 15 residues;

R₀ is NH₂ or NH-(CH₂)**n**-CONH₂, with **n**=1 to 12; and [5]


X is a hydrophobic tail anchored via an amide bond to the N-terminus of the peptide and said hydrophobic tail defining a backbone of 5 to 7 atoms;

wherein said backbone can be substituted by C₁₋₆ alkyl, C₃₋₆ cycloalkyl, or C₆₋₁₂ aryl[₃],


and said backbone comprises at least one rigidifying moiety connected to at least two atoms of the backbone;

said moiety is selected from the group consisting of [~~double bond,~~] triple bond, saturated or unsaturated C₃₋₉ cycloalkyl, and C₆₋₁₂ aryl.


2. (Amended) The hydrophobic GRF analog of claim 1, wherein X is selected from the group consisting of:




1 (R = H or CH₃ or CH₂CH₃)₁




2 (R = H or CH₃ or CH₂CH₃)₁




3 (R = H or CH₃ or CH₂CH₃)₁




4 (R = H or CH₃ or CH₂CH₃)₁




5 (R = H or CH₃ or CH₂CH₃)₁




6 (R = H or CH₃ or CH₂CH₃)₁




7 (R = H or CH₃ or CH₂CH₃)₁




8 (R = H or CH₃ or CH₂CH₃)₁




9 (R = H or CH₃)₁




10 (R = H or CH₃ or CH₂CH₃)₁



11 (R = H or CH₃ or CH₂CH₃)₁



12 (R = H or CH₃); and



13

4. (Amended) ~~[Use of GRF analog as claimed in claim 1 for the manufacture of a medicament]~~ A method for increasing the level of growth hormone in a patient, ~~[which comprises]~~ the method comprising administering to said patient an effective amount of ~~[said]~~ a GRF analog as claimed in claim 1.

5. (Amended) A method for the diagnosis of growth hormone deficiency ~~[deficiencies]~~ in ~~[patients]~~ a patient, ~~[which comprises]~~ the method comprising administering to said patient an effective amount of a GRF analog as claimed in claim 1 and measuring ~~[the]~~ growth hormone response.

6. (Amended) ~~[Use of GRF analog as claimed in claim 1 for the manufacture of a medicament]~~ A method for the treatment of pituitary dwarfism or growth retardation in a patient, ~~[which comprises]~~ the method comprising administering to said patient an effective amount of ~~[said]~~ a GRF analog as claimed in claim 1.

7. (Amended) ~~[Use of GRF analog as claimed in claim 1 for the manufacture of a medicament]~~ A method for the treatment of wound or bone healing in a patient, ~~[which comprises]~~ the method comprising administering to said patient an effective amount of ~~[said]~~ a GRF analog as claimed in claim 1.

8. (Amended) ~~[Use of GRF analog as claimed in claim 1 for the manufacture of a medicament]~~ A method for the treatment of osteoporosis in a patient, ~~[which comprises]~~ the method comprising administering to said patient an effective amount of ~~[said]~~ a GRF analog as claimed in claim 1.

9. (Amended) ~~[Use of GRF analog as claimed in claim 1 for the manufacture of a medicament]~~ A method for improving protein anabolism in a human or an animal, ~~[which comprises]~~ the method comprising administering to said human or animal an effective amount of ~~[said]~~ a GRF analog as claimed in claim 1.

10. (Amended) ~~[Use of GRF analog as claimed in claim 1 for the manufacture of a medicament]~~ A method for inducing a lipolytic effect in a human or an animal inflicted with clinical obesity, ~~[which comprises]~~ the method comprising administering to ~~[said patient]~~ the human or animal an effective amount of ~~[said]~~ a GRF analog as claimed in claim 1.

11. (Amended) ~~[Use of GRF analog as claimed in claim 1 for the manufacture of a medicament]~~ A method for the overall upgrading of somatroph function in a human or an animal, ~~[which comprises]~~ the method comprising administering to ~~[said patient]~~ the human or animal an effective amount of ~~[said]~~ a GRF analog as claimed in claim 1.